These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 28836858)

  • 1. Investigational anabolic agents for the treatment of osteoporosis: an update on recent developments.
    Dede AD; Makras P; Anastasilakis AD
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1137-1144. PubMed ID: 28836858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis.
    Chew CK; Clarke BL
    Maturitas; 2017 Mar; 97():53-60. PubMed ID: 28159062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide.
    Bhattacharyya S; Pal S; Chattopadhyay N
    Biochem Pharmacol; 2019 Aug; 166():185-191. PubMed ID: 31136739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis.
    Toulis KA; Anastasilakis AD; Polyzos SA; Makras P
    Hormones (Athens); 2011; 10(3):174-95. PubMed ID: 22001129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis.
    Augustine M; Horwitz MJ
    Curr Osteoporos Rep; 2013 Dec; 11(4):400-6. PubMed ID: 24078470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anabolic therapies for osteoporosis.
    Uihlein AV; Leder BZ
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abaloparatide and the Spine: A Narrative Review.
    Thompson JC; Wanderman N; Anderson PA; Freedman BA
    Clin Interv Aging; 2020; 15():1023-1033. PubMed ID: 32636617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New anabolic therapies for osteoporosis.
    Minisola S; Cipriani C; Occhiuto M; Pepe J
    Intern Emerg Med; 2017 Oct; 12(7):915-921. PubMed ID: 28780668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis.
    Polyzos SA; Makras P; Efstathiadou Z; Anastasilakis AD
    Expert Opin Investig Drugs; 2015 Feb; 24(2):145-57. PubMed ID: 25316089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigational anabolic therapies for osteoporosis.
    Trivedi R; Goswami R; Chattopadhyay N
    Expert Opin Investig Drugs; 2010 Aug; 19(8):995-1005. PubMed ID: 20629616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Update and perspectives of anabolic therapies for osteoporosis].
    Endo I; Matsumoto T
    Clin Calcium; 2012 Mar; 22(3):327-33. PubMed ID: 22370299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoanabolic and dual action drugs.
    Tabacco G; Bilezikian JP
    Br J Clin Pharmacol; 2019 Jun; 85(6):1084-1094. PubMed ID: 30218587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapies in osteoporosis: PTH-related peptide analogs and inhibitors of sclerostin.
    Rachner TD; Hofbauer LC; Göbel A; Tsourdi E
    J Mol Endocrinol; 2019 Feb; 62(2):R145-R154. PubMed ID: 30389901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of hPTHrP (1-36) as an anabolic therapeutic agent for osteoporosis].
    Takeuchi Y
    Clin Calcium; 2011 Jan; 21(1):28-32. PubMed ID: 21187591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging anabolic agents in the treatment of osteoporosis.
    Lovato C; Lewiecki EM
    Expert Opin Emerg Drugs; 2017 Sep; 22(3):247-257. PubMed ID: 28756709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
    Brixen KT; Christensen PM; Ejersted C; Langdahl BL
    Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging anabolic treatments in osteoporosis.
    Mosekilde L; Tørring O; Rejnmark L
    Curr Drug Saf; 2011 Apr; 6(2):62-74. PubMed ID: 21524248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anabolic agents: what is beyond osteoporosis?
    Liu Y; Levack AE; Marty E; Or O; Samuels BP; Redko M; Lane JM
    Osteoporos Int; 2018 May; 29(5):1009-1022. PubMed ID: 29627891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of parathyroid hormone, parathyroid hormone-related protein, and abaloparatide on collagen 1 expression by mouse cementoblasts and mouse tooth root density.
    Hsu C; He Z; Le Henaff C; Partridge NC
    Am J Orthod Dentofacial Orthop; 2023 Mar; 163(3):378-388.e1. PubMed ID: 36543659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.
    Canalis E
    Eur J Endocrinol; 2018 Feb; 178(2):R33-R44. PubMed ID: 29113980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.